Clene Nanomedicine Announces Over 50% of Subjects Randomized in RESCUE-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8
SALT LAKE CITY, May 26, 2020 /PRNewswire/ — Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced its Australian subsidiary has completed over 50% of participant randomization in the Phase 2 RESCUE-ALS study with its lead nanocatalytic therapy, CNM-Au8,…
Comments Off on Clene Nanomedicine Announces Over 50% of Subjects Randomized in RESCUE-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8